Extracellular Vesicle Delivery Cochlea 2024
EVs aren’t “early research” anymore. Real results are coming in.
Microfluidic droplet electroporation (Science Translational Medicine 2024): Loaded EVs with Cas9 RNP complexes. 10x loading efficiency and 1000x throughput compared to conventional methods. Restored hearing in adult mice with DFNA50 (progressive hearing loss from miR-96 mutation). Adult mice. Not neonatal. That matters.
First human trial: MSC-derived EVs to reduce cochlear implant inflammation. Not gene therapy per se, but it puts EVs in human cochleae. Safety data from this feeds into future therapeutic applications.
Gold nanoparticles (PMC 2024): 52-102 nm particles perfuse the entire cochlear perilymphatic space without disrupting cochlear mechanics. That’s a non-trivial finding. Most delivery methods risk damaging the delicate structures they’re trying to treat.
A666 peptide-coated PLA nanoparticles: Enhanced OHC targeting. This is interesting for STRC specifically because we need OHC-specific delivery.
The trend is clear: non-viral delivery is maturing fast. For STRC, this opens up approaches that bypass the AAV size limit entirely. No packaging constraints if you’re not using AAV.
Connections
- STRC Gene Therapy — non-viral delivery alternative
- Alternative STRC Delivery Hypotheses — EVs as delivery platform
- STRC AAV Vector Design — EVs bypass AAV size constraints
- STRC Anti-AAV Immune Response Model — EVs avoid AAV immune issues entirely